SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has witnessed a significant shift in its valuation parameters, moving from an expensive to a very expensive rating, driven by a surge in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. Despite this, the company’s stock has delivered exceptional returns over multiple time horizons, outperforming the broader Sensex by a wide margin.

The Sensex advanced 1.03% on 20 Mar 2026, yet SMS Pharmaceuticals Ltd outpaced the broader market with a 7.32% gain, touching an intraday high of Rs 388.95. This 4.45-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a market-wide lift.

SMS Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

SMS Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive to an expensive rating, reflecting evolving investor perceptions amid robust stock performance and sector dynamics. This article analyses the recent changes in key valuation metrics such as price-to-earnings (P/E) and price-to-book value (P/BV) ratios, comparing them with historical averages and peer benchmarks to assess the stock’s price attractiveness.

Shares of SMS Pharmaceuticals Ltd declined sharply on 13 Mar 2026, hitting an intraday low of Rs 374.45 as the stock faced significant price pressure, underperforming its sector and broader market indices amid a cautious market environment.

SMS Pharmaceuticals Ltd has reached a significant milestone by hitting a new 52-week high of Rs.433.8, marking a notable surge in its stock price amid a challenging broader market environment.

SMS Pharmaceuticals Ltd surged to an intraday high of Rs 410, marking a new 52-week and all-time peak as the stock demonstrated robust intraday performance with a 7.27% gain, significantly outpacing its sector and broader market indices on 10 Mar 2026.

SMS Pharmaceuticals Ltd has reached a significant milestone by hitting a new 52-week high of Rs.408.5, marking a remarkable surge in its stock price and reflecting strong momentum in the Pharmaceuticals & Biotechnology sector.

SMS Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive to an expensive rating, reflecting a subtle change in price attractiveness. With a current P/E ratio of 39.33 and a P/BV of 4.83, the company’s valuation remains elevated but shows signs of moderation relative to its historical and peer averages. This article analyses these valuation changes in the context of the company’s financial performance, sector dynamics, and market returns to provide investors with a comprehensive view of SMS Pharma’s current standing.

SMS Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 March 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market standing.

SMS Pharmaceuticals Ltd witnessed a significant gap down at market open on 2 Mar 2026, dropping 16.02% to an intraday low of Rs 322.65. This sharp decline reflects heightened market concerns following overnight developments, resulting in a weak start and notable underperformance relative to its sector and benchmark indices.

SMS Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change reflects evolving market perceptions and impacts the stock’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

SMS Pharmaceuticals Ltd has reached a significant milestone by hitting a new 52-week high of Rs 393.9, marking a strong rally in the Pharmaceuticals & Biotechnology sector. This achievement underscores the stock’s robust momentum amid a mixed market environment.

SMS Pharmaceuticals Ltd has reached a significant milestone by hitting a new 52-week high of Rs.393.9, marking a notable surge in its stock price and reflecting strong momentum within the Pharmaceuticals & Biotechnology sector.

SMS Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.